ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.

Establishment Labs to Participate in 41st Annual J.P. Morgan Healthcare Conference

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
December 28, 2022 GMT

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Dec 28, 2022--

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 7:30 a.m. Pacific Time.

A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, over 2.5 million Motiva Implants® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora® tissue expander and Mia Femtech™, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant® and began a clinical trial to support regulatory approval in the United States. Motiva Implants® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at establishmentlabs.com.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20221228005077/en/

CONTACT: Investor/Media Contact:

Raj Denhoy

415-828-1044

rdenhoy@establishmentlabs.com

ADVERTISEMENT

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: SURGERY MEDICAL DEVICES WOMEN CONSUMER HEALTH

SOURCE: Establishment Labs Holdings Inc.

Copyright Business Wire 2022.

PUB: 12/28/2022 08:00 AM/DISC: 12/28/2022 08:01 AM

http://www.businesswire.com/news/home/20221228005077/en